|
Company Overview
ImmunoGenetix
Therapeutics, Inc. is a biotechnology company developing
advanced DNA immunotherapies for HIV infection. DNA
immunotherapies offer
a promising approach to reducing the dependency on anti-HIV drug
cocktails and
diminishing the emergence of drug-resistant HIV strains. They are
relatively inexpensive to produce, readily scaled up, and stable at
ambient
temperatures.
GenePro™
(∆4SHIVku2),
the Company’s lead product candidate incorporates a proprietary DNA
construct that yields high levels of gene expression and non-infectious
HIV
protein production, and induces a robust antibody and cellular immune
response
in animal models. In preclinical efficacy studies, this
immunotherapeutic
candidate controlled viral replication and provided protection against
a deadly
AIDS causing virus in monkeys without viral protein boosts and without
anti-viral therapy.
GenePro™
(∆4SHIVku2)
The
ImmunoGenetix lead product candidate, GenePro™, uses a DNA composition
developed through animal passaging. This approach generates
superior gene expression and subsequent non-infectious HIV protein
production activity, which results in an enhanced immune
response. GenePro™ stimulates a potent cellular and antibody
response that can control the replication of a deadly AIDS-causing
virus in primate animal models without protein or viral vector boosts
and without anti-viral therapy.
Back to the Top
|
